Abstract
In acute respiratory distress syndrome (ARDS) the deficiency of (active) surfactant leads to the progressive deterioration of lung function. If one can reverse the surfactant deficiency one can expect also to improve lung function and ultimately this may reduce the mortality rates in ARDS patients. Therefore, it would be logical to supplement the ARDS lung with exogenous surfactant. Because ARDS is associated with a high mortality rate (> 40%) current investigation on surfactant therapy in adults is focused on reducing mortality in these patients by using exogenous surfactant as a rescue therapy. However, in light of the unique properties of surfactant as a rate-limiting factor in the transfer across the alveolo-capillary membrane, as well as its surface tension lowering properties and the critical role of surfactant in pulmonary host defense, in this chapter we present an outline for future applications of exogenous surfactant.
Chapter PDF
Similar content being viewed by others
Keywords
- Acute Respiratory Distress Syndrome
- Rescue Therapy
- Acute Respiratory Distress Syndrome Patient
- Pulmonary Surfactant
- Improve Lung Function
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Lachmann B (1985) Possible function of bronchial surfactant. Eur J Respir Dis (suppl) 142: 49–61
Bos JA, Wollmer P, Bakker W, Hannappel E, Lachmann B (1992) Clearance of 99mTc-DTPA and experimentally increased alveolar surfactant content. J Appl Physiol 72: 1413–1417
van Iwaarden F, Welmers B, Verhoef J, Haagsman HP, van Golde LM (1990) Pulmonary surfactant protein A enhances the host-defense mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol 2: 91–98
Eijking EP, Gommers D, So KL, Vergeer M, Lachmann B (1993) Surfactant treatment of respiratory failure induced by hydrochloric acid aspiration in rats. Anesthesiology 78: 1145–1151
Verbrugge SJ, Vazquez de Anda G, Gommers D, et al (1998) Exogenous surfactant preserves lung function and reduces alveolar Evans blue dye influx in a rat model of ventilation-induced lung injury. Anesthesiology 89: 467–474
Verbrugge SJ, de Jong JW, Keijzer E, Vazquez de Anda G, Lachmann B (1999) Purine in bronchoalveolar lavage fluid as a marker of ventilation-induced lung injury. Crit Care Med 27: 779–783
Haitsma JJ, Uhlig S, Goggel R, Verbrugge SJ, Lachmann U, Lachmann B (2000) Ventilator-induced lung injury leads to loss of alveolar and systemic compartmentalization of tumor necrosis factor-alpha. Intensive Care Med 26: 1515–1522
Ranieri VM, Giunta F, Suter PM, Slutsky AS (2000) Mechanical ventilation as a mediator of multisystem organ failure in acute respiratory distress syndrome. JAMA 284: 43–44
Haitsma JJ, Uhlig S, Lachmann U, Verbrugge SJ, Poelma DL, Lachmann B (2002) Exogenous surfactant reduces ventilator-induced decompartmentalization of tumor necrosis factor alpha in absence of positive end-expiratory pressure. Intensive Care Med 28: 1131–1137
Eijking EP, van Daal GJ, Tenbrinck R, et al (1991) Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats. Intensive Care Med 17: 475–478
van Daal GJ, So KL, Gommers D, et al (1991) Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. Anesth Analg 72: 589–595
Walmrath D, Grimminger F, Pappert D, et al (2002) Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J 19: 805–810
van ‘t Veen A, Gommers D, Lachmann B (1997) Rationale for surfactant therapy in pneumonia. In: Vincent JL (ed) Yearbook in Intensive Care and Emergency Medicine. Springer, Berlin Heidelberg, pp 638–653
Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W (1995) Inhalation of antibiotics in cystic fibrosis. Eur Respir J 8: 1594–1604
Kharasch VS, Sweeney TD, Fredberg J, et al (1991) Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis 144: 909–913
Enhorning G, Duffy LC, Welliver RC (1995) Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 151: 554–556
van ‘t Veen A, Mouton JW, Gommers D, Lachmann B (1996) Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. Br J Pharmacol 119: 1145–1148
Gommers D, van ‘t Veen A, Verbrugge SJC, Lachmann B (1998) Comparison of eight different surfactant preparations on improvement of blood gases in lung-lavaged rats. Appl Cardiopulm Pathophysiol 7: 95–102
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Haitsma, J.J., Lachmann, R.A., Lachmann, B. (2003). Surfactant Therapy: Beyond a Rescue Therapy for ARDS. In: Vincent, JL. (eds) Intensive Care Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-5548-0_32
Download citation
DOI: https://doi.org/10.1007/978-1-4757-5548-0_32
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4757-5550-3
Online ISBN: 978-1-4757-5548-0
eBook Packages: Springer Book Archive